Camber Capital Management LP Exelixis, Inc. Transaction History

Camber Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $23.8 Million - $28.4 Million	-1,250,000 Reduced 80.65%	300,000 $6.56 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $3.26 Million - $3.88 Million	200,000 Added 14.81%	1,550,000 $30.1 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $4.7 Million - $6.68 Million	-300,000 Reduced 18.18%	1,350,000 $21.2 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $23.5 Million - $31.3 Million	1,350,000 Added 450.0%	1,650,000 $34.4 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $5.11 Million - $6.8 Million	300,000 New	300,000 $6.8 Million

566

251M

1.45M

1.13M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Camber Capital Management LP with notifications on news.